Other analysts have also recently issued research reports about the stock. Deutsche Bank AG reissued a buy rating and issued a GBX 5,600 ($73.10) price target on shares of Shire PLC in a research note on Monday, June 13th. Royal Bank Of Canada reissued an outperform rating on shares of Shire PLC in a research note on Friday, July 22nd. JPMorgan Chase & Co. reissued an overweight rating and issued a GBX 6,300 ($82.23) price target on shares of Shire PLC in a research note on Tuesday, August 16th. Jefferies Group increased their price target on shares of Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the company a buy rating in a research note on Wednesday, August 3rd. Finally, Credit Suisse Group AG increased their price target on shares of Shire PLC from GBX 5,000 ($65.27) to GBX 5,200 ($67.88) and gave the company an outperform rating in a research note on Wednesday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of GBX 5,828 ($76.07).
Shire PLC (LON:SHP) opened at 5006.00 on Tuesday. The firm has a 50-day moving average of GBX 4,985.30 and a 200 day moving average of GBX 4,508.27. The stock’s market capitalization is GBX 34.18 billion. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00.
The company also recently disclosed a dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 8th will be issued a GBX 3.51 ($0.05) dividend. The ex-dividend date of this dividend is Thursday, September 8th. This represents a dividend yield of 0.07%.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.